CURIS Share Price | Curis Lifesciences Ltd Stock Analysis & Recommendation

Q: What does Curis Lifescien. do?

Overview:Curis Lifesciences Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.History:Curis Lifesciences Limited was incorporated as a Private Limited Company in 2016 after being originally formed as a Partnership Firm in 2010. The latest quarterly results report net sales and profit for June 2025.Financial Snapshot:Net Sales: 20 Cr (Quarterly Results - Jun 2025) Net Profit: 3 Cr (Quarterly Results - Jun 2025) Market Cap: INR 103 Cr (Micro Cap)Key Metrics:P/E: 16.00 Industry P/E: 37 Dividend Yield: 0.00% Debt-Equity: 0.39 Return on Equity: 14.63% Price to Book: 2.19 Contact Details:Registrar Address: Not available. Phone: N/A Email: N/A Website: N/A

Q: Who are the peers of the Curis Lifescien.?

Peers: The peers of Curis Lifescien. are Vaishali Pharma, Sotac Pharma., Concord Drugs, Denis Chem Lab, Godavari Drugs, Tyche Industries, Veerhealth Care, Mercury Labs, Pharmaids Pharma, and Asston Pharmaceu.Quality Snapshot: Excellent management risk is observed at Denis Chem Lab and Tyche Industries, while Average management risk is found at Sotac Pharma., Godavari Drugs, Mercury Labs, and Asston Pharmaceu. Below Average management risk is noted at Vaishali Pharma, Concord Drugs, Veerhealth Care, and Pharmaids Pharma. In terms of Growth, Good growth is seen at Veerhealth Care, Average growth at Sotac Pharma. and Pharmaids Pharma, and Below Average growth at Vaishali Pharma, Concord Drugs, Denis Chem Lab, Godavari Drugs, Tyche Industries, Mercury Labs, and Asston Pharmaceu. For Capital Structure, Excellent capital structure is noted at Denis Chem Lab, Tyche Industries, and Mercury Labs, while Average capital structure is found at Sotac Pharma. and Asston Pharmaceu, and Below Average capital structure at Vaishali Pharma, Concord Drugs, Godavari Drugs, Veerhealth Care, and Pharmaids Pharma.Return Snapshot: The peer with the highest 1-year return is Vaishali Pharma at -34.15%, while Curis Lifescien. has a 1-year return of N/A, indicating it cannot be compared directly. The peer with the lowest 1-year return is also Vaishali Pharma at -34.15%. Additionally, all peers have a six-month return of 0.00%, indicating no negative returns in that timeframe.

Technical Trend Update: Curis Lifescien. witnessed a change in Technical Grade on 01 Sep 2026. Click here to discover latest technical change!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

10.0 k (-57.63%) Volume

Shareholding (Mar 2026)

FII

1.19%

Held by 3 FIIs

DII

5.80%

Held by 0 DIIs

Promoter

68.03%

Why is Curis Lifesciences Ltd falling/rising?

02-Sep-2026

As of 01-Sep, Curis Lifesciences Ltd's stock price is rising to 137.50, reflecting a 0.7% increase. This growth is driven by strong performance against the Sensex, significant gains over the past month and year-to-date, and robust investor participation.

View full answer

Which are the latest news on Curis Lifescien.?

02-Sep-2026

No latest news for Curis Lifescien. found.

What does Curis Lifescien. do?

01-Sep-2026

Curis Lifesciences Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 20 Cr and a net profit of 3 Cr for June 2025. Key metrics include a P/E ratio of 16.00 and a market cap of INR 103 Cr.

View full answer

Who are the peers of the Curis Lifescien.?

01-Sep-2026

Curis Lifescien's peers include Vaishali Pharma, Sotac Pharma, and Denis Chem Lab, among others. Management risk varies from excellent at Denis Chem Lab to below average at Vaishali Pharma, with growth and capital structure also showing a range from good to below average across peers.

View full answer

How big is Curis Lifescien.?

01-Sep-2026

As of 31st August, Curis Lifesciences Ltd has a market capitalization of 103.00 Cr, with recent net sales of 9.12 Cr and a net profit of 1.20 Cr for the quarter ending June 2024. Shareholder's funds are 16.23 Cr, and total assets amount to 42.53 Cr as of March 2025.

View full answer

Compare Curis Lifescien. with Similar Stocks

Pharmaids Pharma Makers Labs.Krebs Biochem

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 112 Cr (Micro Cap)

P/E

16.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.39

Return on Equity

14.63%

Price to Book

2.35

Revenue and Profits:

Net Sales:

20 Cr

(Quarterly Results - Jun 2025)

Net Profit:

3 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

25.68%

6 Months

42.02%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Curis Lifescien. for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

6.98

Debt to EBITDA (avg)

1.59

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

1.29

Tax Ratio

27.72%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.99%

ROCE (avg)

25.36%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.35

EV to EBIT

12.42

EV to EBITDA

11.64

EV to Capital Employed

1.97

EV to Sales

2.14

PEG Ratio

Dividend Yield

ROCE (Latest)

15.86%

ROE (Latest)

14.63%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

KST

Dow Theory

Mildly Bullish

No Trend

OBV

Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 3 FIIs (1.19%)

Promoter with highest holding

Pawasia Siddhant J (19.05%)

Highest Public shareholder

SS Corporate Securities Limited (2.81%)

Individual Investors Holdings

14.38%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19.50",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.23",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.29",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "2.87",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.69%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is -18.77% vs 116.10% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 5.25% vs 81.82% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "27.91",
          "val2": "34.36",
          "chgp": "-18.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.99",
          "val2": "6.93",
          "chgp": "-13.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.43",
          "val2": "0.61",
          "chgp": "-29.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.04",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "4.21",
          "val2": "4.00",
          "chgp": "5.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.46%",
          "val2": "20.17%",
          "chgp": "1.29%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "47.41",
          "val2": "35.40",
          "chgp": "33.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10.22",
          "val2": "8.05",
          "chgp": "26.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.72",
          "val2": "0.79",
          "chgp": "-8.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.02",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "7.08",
          "val2": "5.07",
          "chgp": "39.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.56%",
          "val2": "22.74%",
          "chgp": "-1.18%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 20.63% vs 41.34% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 11.43% vs 27.52% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "60.63",
          "val2": "50.26",
          "chgp": "20.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "11.13",
          "val2": "10.74",
          "chgp": "3.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.14",
          "val2": "1.11",
          "chgp": "2.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.01",
          "val2": "0.01",
          "chgp": "-200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "6.92",
          "val2": "6.21",
          "chgp": "11.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "18.36%",
          "val2": "21.37%",
          "chgp": "-3.01%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Jun'25 - QoQ

Jun'25

Change(%)

Net Sales

19.50

Operating Profit (PBDIT) excl Other Income

4.23

Interest

0.29

Exceptional Items

0.00

Standalone Net Profit

2.87

Operating Profit Margin (Excl OI)

21.69%

NA%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Mar'25

Change(%)

Net Sales

27.91

34.36

-18.77%

Operating Profit (PBDIT) excl Other Income

5.99

6.93

-13.56%

Interest

0.43

0.61

-29.51%

Exceptional Items

0.00

0.04

-100.00%

Standalone Net Profit

4.21

4.00

5.25%

Operating Profit Margin (Excl OI)

21.46%

20.17%

1.29%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2025 is -18.77% vs 116.10% in Mar 2025

Standalone Net Profit

Growth in half year ended Sep 2025 is 5.25% vs 81.82% in Mar 2025

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Jun'25

Jun'25

Change(%)

Net Sales

47.41

35.40

33.93%

Operating Profit (PBDIT) excl Other Income

10.22

8.05

26.96%

Interest

0.72

0.79

-8.86%

Exceptional Items

0.00

-0.02

100.00%

Standalone Net Profit

7.08

5.07

39.64%

Operating Profit Margin (Excl OI)

21.56%

22.74%

-1.18%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Standalone) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

60.63

50.26

20.63%

Operating Profit (PBDIT) excl Other Income

11.13

10.74

3.63%

Interest

1.14

1.11

2.70%

Exceptional Items

-0.01

0.01

-200.00%

Standalone Net Profit

6.92

6.21

11.43%

Operating Profit Margin (Excl OI)

18.36%

21.37%

-3.01%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 20.63% vs 41.34% in Mar 2025

Standalone Net Profit

YoY Growth in year ended Mar 2026 is 11.43% vs 27.52% in Mar 2025

All Annual Results

Company CV

About Curis Lifesciences Ltd

Curis Lifesciences Ltd

Micro Cap

Pharmaceuticals & Biotechnology

Curis Lifesciences Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name and style of "M/s Loreto Pharmaceutacals", pursuant to a Deed of Partnership dated 2 June, 2010. Thereafter " M/s Loreto Pharmaceutacals" was converted from Partnership Firm to a Private Limited Company as "Curis Lifesciences Private Limited" and received a Certificate of Incorporation dated on March 23rd, 2016 issued by Registrar of Companies, Ahmedabad.

Company Coordinates

No Company Details Available